Oppenheimer & Co’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Oppenheimer & Co’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-171	Closed	-$1.39K	–	1500
2023 Q1	$1.39K	Hold	171	–	–	﹤0.01%	1378
2022 Q4	$2.03K	Hold	171	–	–	﹤0.01%	1348
2022 Q3	$2K	Hold	171	–	–	﹤0.01%	1359
2022 Q2	$6K	Hold	171	–	–	﹤0.01%	1402
2022 Q1	$7K	Hold	171	–	–	﹤0.01%	1462
2021 Q4	$7K	Hold	171	–	–	﹤0.01%	1484
2021 Q3	$12K	Hold	171	–	–	﹤0.01%	1484
2021 Q2	$13K	Hold	171	–	–	﹤0.01%	1499
2021 Q1	$11K	Hold	171	–	–	﹤0.01%	1432
2020 Q4	$6K	Hold	171	–	–	﹤0.01%	1338
2020 Q3	$9K	Sell	171 -58	-25%	-$3.44K	﹤0.01%	1272
2020 Q2	$9K	Hold	229	–	–	﹤0.01%	1247
2020 Q1	$6K	Hold	229	–	–	﹤0.01%	1187
2019 Q4	$11K	Hold	229	–	–	﹤0.01%	1270
2019 Q3	$11K	Hold	229	–	–	﹤0.01%	1249
2019 Q2	$21K	Sell	229 -14	-6%	-$1.7K	﹤0.01%	1292
2019 Q1	$36K	Hold	243	–	–	﹤0.01%	1330
2018 Q4	$38K	Buy	+243	New	+$46.6K	﹤0.01%	1218

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Oppenheimer & Co's DMK Position: Q2 2023 in Review

Oppenheimer & Co sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 171 shares — an estimated $1.39K sold.

Oppenheimer & Co first reported a position in DMK in Q4 2018 and held it in 18 quarters. The position peaked at $38K in Q4 2018. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Oppenheimer & Co reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Oppenheimer & Co sold 171 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $1.39K.
Oppenheimer & Co first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2018 and held it in 18 quarters.
Oppenheimer & Co's DMK Pharmaceuticals Corporation Common Stock position peaked at $38K in Q4 2018.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.